Not Just Anticoagulation-New and Old Applications of Heparin

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2022 Oct 27

PMID 36296562

Authors

Lixuan Zang

Haomiao Zhu

Kun Wang

Yonghui Liu

Fan Yu

Wei Zhao

Affiliations

Soon will be listed here.

Abstract

In recent decades, heparin, as the most important anticoagulant drug, has been widely used in clinical settings to prevent and treat thrombosis in a variety of diseases. However, with in-depth research, the therapeutic potential of heparin is being explored beyond anticoagulation. To date, heparin and its derivatives have been tested in the protection against and repair of inflammatory, antitumor, and cardiovascular diseases. It has also been explored as an antiangiogenic, preventive, and antiviral agent for atherosclerosis. This review focused on the new and old applications of heparin and discussed the potential mechanisms explaining the biological diversity of heparin.

Citing Articles

The Efficacy of Heparin and Nitroglycerin in Managing Vascular Embolism Complications from Polycaprolactone (PCL) Fillers: A Clinical Study.

Khan A, Wang T, Zhang P, Qi L, Gong L, Cui H Aesthetic Plast Surg. 2025; .

PMID: 39747416 DOI: 10.1007/s00266-024-04608-8.

Epidemiology, risk factors and mechanism of breast cancer and atrial fibrillation.

Guo X, Zuo Z, Wang X, Sun Y, Xu D, Liu G Cardiooncology. 2024; 10(1):92.

PMID: 39716319 PMC: 11665102. DOI: 10.1186/s40959-024-00298-y.

Multifaceted Heparin: Diverse Applications beyond Anticoagulant Therapy.

Sultana R, Kamihira M Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39459002 PMC: 11510354. DOI: 10.3390/ph17101362.

The Preventive and Therapeutic Effects of Acute and Severe Inflammatory Disorders with Heparin and Heparinoid.

Song Y, Wu Y, Ding F, Li S, Shen Y, Yang B Biomolecules. 2024; 14(9).

PMID: 39334845 PMC: 11430252. DOI: 10.3390/biom14091078.

Evolution of Hybrid Hydrogels: Next-Generation Biomaterials for Drug Delivery and Tissue Engineering.

Rana M, De la Hoz Siegler H Gels. 2024; 10(4).

PMID: 38667635 PMC: 11049329. DOI: 10.3390/gels10040216.

References

Mori Y, Nakamura S, Kishimoto S, Kawakami M, Suzuki S, Matsui T . Preparation and characterization of low-molecular-weight heparin/protamine nanoparticles (LMW-H/P NPs) as FGF-2 carrier. Int J Nanomedicine. 2010; 5:147-55. PMC: 2865009. DOI: 10.2147/ijn.s8692. View

Tan Q, Tang H, Hu J, Hu Y, Zhou X, Tao Y . Controlled release of chitosan/heparin nanoparticle-delivered VEGF enhances regeneration of decellularized tissue-engineered scaffolds. Int J Nanomedicine. 2011; 6:929-42. PMC: 3124397. DOI: 10.2147/IJN.S18753. View

Zhang T, Liu X, Li H, Wang Z, Chi L, Li J . Characterization of epimerization and composition of heparin and dalteparin using a UHPLC-ESI-MS/MS method. Carbohydr Polym. 2018; 203:87-94. DOI: 10.1016/j.carbpol.2018.08.108. View

Rao N, Argyle B, Xu X, Reynolds P, Walenga J, Prechel M . Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands. Am J Physiol Cell Physiol. 2010; 299(1):C97-110. DOI: 10.1152/ajpcell.00009.2010. View

Hirsh J, Warkentin T, Raschke R, Granger C, Ohman E, Dalen J . Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1998; 114(5 Suppl):489S-510S. DOI: 10.1378/chest.114.5_supplement.489s. View

Naggi A, Gardini C, Pedrinola G, Mauri L, Urso E, Alekseeva A . Structural peculiarity and antithrombin binding region profile of mucosal bovine and porcine heparins. J Pharm Biomed Anal. 2015; 118:52-63. DOI: 10.1016/j.jpba.2015.10.001. View

Atallah J, Khachfe H, Berro J, Assi H . The use of heparin and heparin-like molecules in cancer treatment: a review. Cancer Treat Res Commun. 2020; 24:100192. DOI: 10.1016/j.ctarc.2020.100192. View

Pettila V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost. 2002; 87(2):182-6. View

Lindahl U, Thunberg L, Backstrom G, Riesenfeld J, Nordling K, BJORK I . Extension and structural variability of the antithrombin-binding sequence in heparin. J Biol Chem. 1984; 259(20):12368-76. View

10.

Phillips P, Yalcin M, Cui H, Abdel-Nabi H, Sajjad M, Bernacki R . Increased tumor uptake of chemotherapeutics and improved chemoresponse by novel non-anticoagulant low molecular weight heparin. Anticancer Res. 2011; 31(2):411-9. View

11.

Weitz J . Low-molecular-weight heparins. N Engl J Med. 1997; 337(10):688-98. DOI: 10.1056/NEJM199709043371007. View

12.

Modhiran N, Gandhi N, Wimmer N, Cheung S, Stacey K, Young P . Dual targeting of dengue virus virions and NS1 protein with the heparan sulfate mimic PG545. Antiviral Res. 2019; 168:121-127. DOI: 10.1016/j.antiviral.2019.05.004. View

13.

Rajgopal R, Bear M, Butcher M, Shaughnessy S . The effects of heparin and low molecular weight heparins on bone. Thromb Res. 2007; 122(3):293-8. DOI: 10.1016/j.thromres.2006.10.025. View

14.

Bermejo-Jambrina M, Eder J, Kaptein T, van Hamme J, Helgers L, Vlaming K . Infection and transmission of SARS-CoV-2 depend on heparan sulfate proteoglycans. EMBO J. 2021; 40(20):e106765. PMC: 8521309. DOI: 10.15252/embj.2020106765. View

15.

Tandon R, Sharp J, Zhang F, Pomin V, Ashpole N, Mitra D . Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives. J Virol. 2020; 95(3). PMC: 7925120. DOI: 10.1128/JVI.01987-20. View

16.

Choi J, Kim J, Chung S, Lee N, Park J, Kweon S . Dual mechanistic TRAIL nanocarrier based on PEGylated heparin taurocholate and protamine which exerts both pro-apoptotic and anti-angiogenic effects. J Control Release. 2021; 336:181-191. DOI: 10.1016/j.jconrel.2021.06.019. View

17.

Shukla D, Liu J, Blaiklock P, Shworak N, Bai X, Esko J . A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell. 1999; 99(1):13-22. DOI: 10.1016/s0092-8674(00)80058-6. View

18.

Mousa S, Mohamed S . Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anti-cancer efficacy. Oncol Rep. 2004; 12(4):683-8. View

19.

Szajek A, Chess E, Johansen K, Gratzl G, Gray E, Keire D . The US regulatory and pharmacopeia response to the global heparin contamination crisis. Nat Biotechnol. 2016; 34(6):625-30. PMC: 6516469. DOI: 10.1038/nbt.3606. View

20.

Lussana F, Coppens M, Cattaneo M, Middeldorp S . Pregnancy-related venous thromboembolism: risk and the effect of thromboprophylaxis. Thromb Res. 2012; 129(6):673-80. DOI: 10.1016/j.thromres.2012.01.017. View